López Montesinos, InmaculadaMontero, Maria MilagroSorli Redó, M. LuisaHorcajada Gallego, Juan Pablo2022-07-072022-07-072021López Montesinos I, Montero M, Sorlí L, Horcajada JP. Ceftolozane-tazobactam: when, how and why using it? Rev Esp Quimioter. 2021 Sep; 34 Suppl 1(Suppl1):35-7. DOI: 10.37201/req/s01.10.20210214-3429http://hdl.handle.net/10230/53689Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales. Ceftolozane-tazobactam is formally approved for complicated urinary tract infection, complicated intra-abdominal infection, and hospital-acquired and ventilator-associated bacterial pneumonia. The clinical and microbiological success is over 70-80% in many series. However, resistant mutants to ceftolozane-tazobactam have been already described. Combination therapies with colistin or meropenem could be among the strategies to avoid the resistance emergence.application/pdfengCopyright © The Author 2021. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(http://creativecommons.org/licenses/by-nc/4.0/).info:eu-repo/semantics/articlehttp://dx.doi.org/10.37201/req/s01.10.2021Anti-Bacterial AgentsCephalosporinsCeftolozaneTazobactamColistininfo:eu-repo/semantics/openAccess